Augustine Therapeutics is proud to sponsor the 2024 Global CMT Research Convention, organized by the US CMT Research Foundation, to be held from September 26 ^th to 28 ^th 2024 at the Royal Sonesta Boston, Cambridge, MA.

The event is gathering researchers, biotech and pharma companies, investors, and patients to discuss widely the latest research and development towards finding a cure for Charcot-Marie-Tooth patients. This annual convention enhances the scope and possibilities of research discoveries as a step forward for the people who are living with CMT!

In addition, our team will participate to the 'Researcher Day' on Friday, September 27 ^th 2024:

• Our Vice President Drug Discovery, Dr. Frederik Rombouts will be speaker on the Researcher Day at the session “Therapeutic Approaches That Target the Biology of CMT – 10:15 am EDT.

Dr. Rombouts will provide an update on our first clinical candidate AGT100216 progressing towards First-in-man studies. AGT100216 is a peripheral-restricted selective, orally bioavailable and safe, non-hydroxamate and non-fluoromethyloxadiazole HDAC6 inhibitor. Title: 'Developing Best-in-Class HDAC6 Inhibitors for the treatment of CMT1A'

• Our Executive Chair, Dr. Gerhard Koenig, will be panelist at the session gathering biotech Executive leaders on the theme “Understanding the criteria for pursuing a drug program for CMT” at 5:05 pm EDT.

Dr. Koenig will highlight the groundbreaking science foundations of our HDAC6 program that emerged from the labs of Prof. Ludo Van Den Bosch at the VIB-KU Leuven, and the subsequent robust preclinical data in CMT studies that support our recently announced Series A1 round lead by Asabys Partners, with the participation of Eli Lilly and Company, and the CMT Research Foundation, along historical investors.

Find out details of the event and agenda : Click Here